Genetic variability of human papillomavirus type 18 based on E6, E7 and L1 genes in central China.
Oncogene Proteins, Viral
/ genetics
China
Humans
Phylogeny
Genetic Variation
Human papillomavirus 18
/ genetics
Papillomavirus E7 Proteins
/ genetics
Capsid Proteins
/ genetics
Female
Epitopes, T-Lymphocyte
/ genetics
Papillomavirus Infections
/ virology
Repressor Proteins
/ genetics
Epitopes, B-Lymphocyte
/ genetics
DNA-Binding Proteins
E6
E7 and L1 genes
Epitope prediction
Human papillomavirus (HPV) 18
Variants
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
05 Jul 2024
05 Jul 2024
Historique:
received:
07
05
2024
accepted:
27
06
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
5
7
2024
Statut:
epublish
Résumé
High-risk human papillomavirus (HR-HPV) infection is an important factor for the development of cervical cancer. HPV18 is the second most common HR-HPV after HPV16. In this study, MEGA11 software was used to analyze the variation and phylogenetic tree of HPV18 E6-E7 and L1 genes. The selective pressure to E6, E7 and L1 genes was estimated using pamlX. In addition, the B cell epitopes of L1 amino acid sequences and T cell epitopes of E6-E7 amino acid sequences in HPV18 were predicted by ABCpred server and IEDB website, respectively. A total of 9 single nucleotide variants were found in E6-E7 sequences, of which 2 were nonsynonymous variants and 7 were synonymous variants. Twenty single nucleotide variants were identified in L1 sequence, including 11 nonsynonymous variants and 9 synonymous variants. Phylogenetic analysis showed that E6-E7 and L1 sequences were all distributed in A lineage. In HPV18 E6, E7 and L1 sequences, no positively selected site was found. The nonconservative substitution R545C in L1 affected hypothetical B cell epitope. Two nonconservative substitutions, S82A in E6, and R53Q in E7, impacted multiple hypothetical T cell epitopes. The sequence variation data of HPV18 may lay a foundation for the virus diagnosis, further study of cervical cancer and vaccine design in central China.
Sections du résumé
BACKGROUND
BACKGROUND
High-risk human papillomavirus (HR-HPV) infection is an important factor for the development of cervical cancer. HPV18 is the second most common HR-HPV after HPV16.
METHODS
METHODS
In this study, MEGA11 software was used to analyze the variation and phylogenetic tree of HPV18 E6-E7 and L1 genes. The selective pressure to E6, E7 and L1 genes was estimated using pamlX. In addition, the B cell epitopes of L1 amino acid sequences and T cell epitopes of E6-E7 amino acid sequences in HPV18 were predicted by ABCpred server and IEDB website, respectively.
RESULTS
RESULTS
A total of 9 single nucleotide variants were found in E6-E7 sequences, of which 2 were nonsynonymous variants and 7 were synonymous variants. Twenty single nucleotide variants were identified in L1 sequence, including 11 nonsynonymous variants and 9 synonymous variants. Phylogenetic analysis showed that E6-E7 and L1 sequences were all distributed in A lineage. In HPV18 E6, E7 and L1 sequences, no positively selected site was found. The nonconservative substitution R545C in L1 affected hypothetical B cell epitope. Two nonconservative substitutions, S82A in E6, and R53Q in E7, impacted multiple hypothetical T cell epitopes.
CONCLUSION
CONCLUSIONS
The sequence variation data of HPV18 may lay a foundation for the virus diagnosis, further study of cervical cancer and vaccine design in central China.
Identifiants
pubmed: 38970084
doi: 10.1186/s12985-024-02424-9
pii: 10.1186/s12985-024-02424-9
doi:
Substances chimiques
Oncogene Proteins, Viral
0
Papillomavirus E7 Proteins
0
Capsid Proteins
0
Epitopes, T-Lymphocyte
0
E6 protein, Human papillomavirus type 18
0
E7 protein, Human papillomavirus type 18
0
Repressor Proteins
0
Epitopes, B-Lymphocyte
0
L1 protein, Human papillomavirus type 18
J2D279PEM5
DNA-Binding Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
152Subventions
Organisme : Science and technology plan project of Jingzhou City
ID : 2022HC62
Organisme : Science and technology plan project of Jingzhou City
ID : 2022HC62
Organisme : Science and technology plan project of Jingzhou City
ID : 2022HC62
Organisme : Science and technology plan project of Jingzhou City
ID : 2022HC62
Organisme : Science and technology plan project of Jingzhou City
ID : 2022HC62
Organisme : Science and technology plan project of Jingzhou City
ID : 2022HC62
Organisme : Key research and development plan project supporting local special funds in the field of comprehensive health of Hubei Province
ID : 2022BCE029
Organisme : Key research and development plan project supporting local special funds in the field of comprehensive health of Hubei Province
ID : 2022BCE029
Organisme : Key research and development plan project supporting local special funds in the field of comprehensive health of Hubei Province
ID : 2022BCE029
Organisme : Key research and development plan project supporting local special funds in the field of comprehensive health of Hubei Province
ID : 2022BCE029
Organisme : Key research and development plan project supporting local special funds in the field of comprehensive health of Hubei Province
ID : 2022BCE029
Organisme : Key research and development plan project supporting local special funds in the field of comprehensive health of Hubei Province
ID : 2022BCE029
Informations de copyright
© 2024. The Author(s).
Références
Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public Health. 2023;16(4):626–31.
pubmed: 36868166
doi: 10.1016/j.jiph.2023.02.014
Cubie HA. Diseases associated with human papillomavirus infection. Virology. 2013;445(1–2):21–34.
pubmed: 23932731
doi: 10.1016/j.virol.2013.06.007
Yu L, Majerciak V,Zheng ZM. Correction: Yu et al. HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation. Int J Mol Sci. 2022;23:4943. Int J Mol Sci. 2022; 23(14).
Rahangdale L, Mungo C, O’Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. Br Med J. 2022;379: e070115.
doi: 10.1136/bmj-2022-070115
Alcaniz Boada E, Cuschieri K, Graham C, Moncur S, Bhatia R. Agreement between L1 and E6/E7-based assays for detection of high-risk HPV in cervical, oropharyngeal and penile cancers. J Clin Pathol. 2023;76(7):467–73.
pubmed: 35135864
doi: 10.1136/jclinpath-2021-208054
Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. Trends Microbiol. 2018;26(2):158–68.
pubmed: 28823569
doi: 10.1016/j.tim.2017.07.007
Estêvão D, Costa NR, Gil da Costa RM,Medeiros R. Hallmarks of HPV carcinogenesis: The role of E6, E7 and E5 oncoproteins in cellular malignancy. Biochim Biophys Acta Gene Regul Mech. 2019; 1862(2):153–162.
Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2018;5:46–58.
pubmed: 29277575
doi: 10.1016/j.pvr.2017.12.006
Bletsa G, Zagouri F, Amoutzias GD, Nikolaidis M, Zografos E, Markoulatos P, et al. Genetic variability of the HPV16 early genes and LCR. Present and future perspectives. Expert Rev Mol Med. 2021;23:e19.
Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529(7587):541–5.
pubmed: 26789255
pmcid: 4853763
doi: 10.1038/nature16481
Aarthy M, Kumar D, Giri R, Singh SK. E7 oncoprotein of human papillomavirus: Structural dynamics and inhibitor screening study. Gene. 2018;658:159–77.
pubmed: 29535023
doi: 10.1016/j.gene.2018.03.026
Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89(24):12180–4.
pubmed: 1334560
pmcid: 50722
doi: 10.1073/pnas.89.24.12180
Yang R, Wheeler CM, Chen X, Uematsu S, Takeda K, Akira S, et al. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer. J Virol. 2005;79(11):6741–50.
pubmed: 15890912
pmcid: 1112150
doi: 10.1128/JVI.79.11.6741-6750.2005
Gurgel AP, Chagas BS, do Amaral CM, Nascimento KC, Leal LR, Silva Neto Jda C, et al. Prevalence of human papillomavirus variants and genetic diversity in the L1 gene and long control region of HPV16, HPV31, and HPV58 found in North-East Brazil. Biomed Res Int. 2015;2015:130828.
Garbuglia AR, Lapa D, Sias C, Capobianchi MR, Del Porto P. The use of both therapeutic and prophylactic vaccines in the therapy of papillomavirus disease. Front Immunol. 2020;11:188.
pubmed: 32133000
pmcid: 7040023
doi: 10.3389/fimmu.2020.00188
Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology. 2013;445(1–2):232–43.
pubmed: 23998342
doi: 10.1016/j.virol.2013.07.018
Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125(7):1030–7.
pubmed: 30748006
doi: 10.1002/cncr.32003
Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35.
pubmed: 20473886
doi: 10.1002/ijc.25396
Sait K, Turki R, Abuzenadah AM, Jiffiri OH, Bohmaidah A, Sohrab SS. Genetic diversity and phylogenetic analysis of HPV 16 & 18 variants isolated from cervical specimens of women in Saudi Arabia. Saudi J Biol Sci. 2019;26(2):317–24.
pubmed: 31485171
doi: 10.1016/j.sjbs.2018.05.005
Li T, Yang Z, Zhang C, Wang S, Mei B. Genetic variation of E6 and E7 genes of human papillomavirus type 16 from central China. Virol J. 2023;20(1):217.
pubmed: 37759219
pmcid: 10537582
doi: 10.1186/s12985-023-02188-8
Kim N, Park JS, Kim JE, Park JH, Park H, Roh EY, et al. Fifteen new nucleotide substitutions in variants of human papillomavirus 18 in Korea : Korean HPV18 variants and clinical manifestation. Virol J. 2020;17(1):70.
pubmed: 32448303
pmcid: 7245819
doi: 10.1186/s12985-020-01337-7
Sun Z, Liu J, Wang G, Zhou W, Liu C, Ruan Q. Variant lineages of human papillomavirus type 18 in Northeast China populations characterized by sequence analysis of E6, E7, and L1 regions. Int J Gynecol Cancer. 2012;22(6):930–6.
pubmed: 22622951
doi: 10.1097/IGC.0b013e318253a994
Xu HH, Zheng LZ, Lin AF, Dong SS, Chai ZY, Yan WH. Human papillomavirus (HPV) 18 genetic variants and cervical cancer risk in Taizhou area. China Gene. 2018;647:192–7.
pubmed: 29331480
doi: 10.1016/j.gene.2018.01.037
Simelela PN. WHO global strategy to eliminate cervical cancer as a public health problem: An opportunity to make it a disease of the past. Int J Gynaecol Obstet. 2021;152(1):1–3.
pubmed: 33269466
doi: 10.1002/ijgo.13484
Liu H, Ma H, Li Y, Zhao H. Advances in epigenetic modifications and cervical cancer research. Biochim Biophys Acta Rev Cancer. 2023;1878(3): 188894.
pubmed: 37011697
doi: 10.1016/j.bbcan.2023.188894
Chen AA, Gheit T, Franceschi S, Tommasino M, Clifford GM. Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide. J Virol. 2015;89(20):10680–7.
pubmed: 26269181
pmcid: 4580183
doi: 10.1128/JVI.01747-15
Yang Z, Zhang C, Luo P, Ye M, Gong Q, Mei B. Genetic variability of E6 and E7 genes of human papillomavirus type 58 in Jingzhou, Hubei Province of central China. Virol J. 2022;19(1):71.
pubmed: 35459244
pmcid: 9034476
doi: 10.1186/s12985-022-01801-6
Muñoz-Bello JO, Carrillo-García A, Lizano M. Epidemiology and molecular biology of HPV variants in cervical cancer: the state of the art in Mexico. Int J Mol Sci. 2022;23(15):8566.
pubmed: 35955700
pmcid: 9368912
doi: 10.3390/ijms23158566
De la Cruz-Hernández E, García-Carrancá A, Mohar-Betancourt A, Dueñas-González A, Contreras-Paredes A, Pérez-Cardenas E, et al. Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J Gen Virol. 2005;86(Pt 9):2459–68.
pubmed: 16099904
doi: 10.1099/vir.0.80945-0
Singini MG, Singh E, Bradshaw D, Ramaliba T, Chen WC, Motlhale M, et al. Usefulness of high-risk HPV early oncoprotein (E6 and E7) serological markers in the detection of cervical cancer: A systematic review and meta-analysis. J Med Virol. 2023;95(1): e27900.
pubmed: 35641882
doi: 10.1002/jmv.27900
Yang L, Yang H, Wu K, Shi X, Ma S, Sun Q. Prevalence of HPV and variation of HPV 16/HPV 18 E6/E7 genes in cervical cancer in women in South West China. J Med Virol. 2014;86(11):1926–36.
pubmed: 25111286
doi: 10.1002/jmv.24043
Wang Y, Han S, Wang X, Song S, Wang X. Characteristics of human papillomavirus infection among females and the genetic variations of HPV18 and HPV58 in Henan province, China. Sci Rep. 2023;13(1):2252.
pubmed: 36755053
pmcid: 9908864
doi: 10.1038/s41598-022-24641-4
De Boer MA, Peters LA, Aziz MF, Siregar B, Cornain S, Vrede MA, et al. Human papillomavirus type 18 variants: histopathology and E6/E7 polymorphisms in three countries. Int J Cancer. 2005;114(3):422–5.
pubmed: 15551313
doi: 10.1002/ijc.20727
Yamaguchi-Naka M, Onuki M, Tenjimbayashi Y, Hirose Y, Tasaka N, Satoh T, et al. Molecular epidemiology of human papillomavirus 18 infections in Japanese Women. Infect Genet Evol. 2020;83: 104345.
pubmed: 32360473
doi: 10.1016/j.meegid.2020.104345
Alsanea M, Alsaleh A, Obeid D, Alhadeq F, Alahideb B, Alhamlan F. Genetic variability in the E6, E7, and L1 genes of human papillomavirus types 16 and 18 among women in Saudi Arabia. Viruses. 2022;15(1):109.
pubmed: 36680149
pmcid: 9862970
doi: 10.3390/v15010109
Shen M, Ding X, Li T, Chen G, Zhou X. Sequence variation analysis of HPV-18 isolates in southwest China. PLoS ONE. 2013;8(2):e56614.
pubmed: 23451059
pmcid: 3581518
doi: 10.1371/journal.pone.0056614
van der Weele P, Meijer C, King AJ. High whole-genome sequence diversity of human papillomavirus type 18 isolates. Viruses. 2018;10(2):68.
pubmed: 29414918
pmcid: 5850375
doi: 10.3390/v10020068
Chen Z, Jing Y, Wen Q, Ding X, Zhang S, Wang T, et al. L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis. Virol J. 2016;13(1):167.
pubmed: 27717385
pmcid: 5055703
doi: 10.1186/s12985-016-0629-9
Yang Z, Wong WS, Nielsen R. Bayes empirical bayes inference of amino acid sites under positive selection. Mol Biol Evol. 2005;22(4):1107–18.
pubmed: 15689528
doi: 10.1093/molbev/msi097
Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res. 2017;2017:2680160.
pubmed: 29445754
pmcid: 5763123
doi: 10.1155/2017/2680160
Hu D, Irving AT. Massively-multiplexed epitope mapping techniques for viral antigen discovery. Front Immunol. 2023;14:1192385.
pubmed: 37818363
pmcid: 10561112
doi: 10.3389/fimmu.2023.1192385
Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S367–s378.
pubmed: 34590141
pmcid: 8577198
doi: 10.1093/infdis/jiaa621
Chenzhang Y, Wen Q, Ding X, Cao M, Chen Z, Mu X, et al. Identification of the impact on T- and B- cell epitopes of human papillomavirus type-16 E6 and E7 variant in Southwest China. Immunol Lett. 2017;181:26–30.
pubmed: 27693214
doi: 10.1016/j.imlet.2016.09.013
Mo Y, Ma J, Zhang H, Shen J, Chen J, Hong J, et al. Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives. Front Cell Infect Microbiol. 2022;12: 909223.
pubmed: 35860379
pmcid: 9289603
doi: 10.3389/fcimb.2022.909223
Chen Z, Jing Y, Wen Q, Ding X, Wang T, Mu X, et al. Correction: E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China. PLoS ONE. 2017;12(7): e0181475.
pubmed: 28700689
pmcid: 5507315
doi: 10.1371/journal.pone.0181475
He J, Yang Y, Chen Z, Liu Y, Bao S, Zhao Y, et al. Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China. Virol J. 2019;16(1):72.
pubmed: 31138240
pmcid: 6537359
doi: 10.1186/s12985-019-1168-y